Key result
The review highlights the cardioprotective, anti-ischemic, and antiatherogenic effects of the ACE inhibitor zofenopril in patients with cardiovascular diseases.
This review highlights the cardioprotective, anti-ischemic, and antiatherogenic properties of zofenopril, supporting its use in patients with cardiovascular disease and prior myocardial infarction.
May support zofenopril consideration post-MI; leaves open prospective RCTs for confirmation.
The given review discusses the use of angiotensin-converting enzyme (ACE) inhibitors in patients with cardiovascular diseases, including those with prior acute myocardial infarction. The paper places particular emphasis on the currently available ACE inhibitor zofenopril. It discusses its special pharmacological properties and considers its additional effects associated with cardioprotective, anti-ischemic, antiatherogenic effects. The review provides a rationale for the clinical efficacy of zofenopril and a possibility for its wider clinical application.
No takes yet. Share an insight, caveat, or question.
М. Г. Бубнова (2013) conducted a review in Cardiovascular diseases, including prior acute myocardial infarction. Zofenopril was evaluated. The review highlights the cardioprotective, anti-ischemic, and antiatherogenic effects of the ACE inhibitor zofenopril in patients with cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: